HCM
OMED

Highbridge Capital Management’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Highbridge Capital Management’s Portfolio OMED Stock Details OMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-49,372
Closed -$455K – 1883
2017
Q1 		$455K Buy
49,372
+12,698
+35% +$112K 0.01% 950
2016
Q4 		$283K Sell
36,674
-6,444
-15% -$59.2K 0.01% 1002
2016
Q3 		$493K Buy
+43,118
New +$502K 0.01% 791

Other funds holding OMED

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Highbridge Capital Management's OMED Position: Q2 2017 in Review

Highbridge Capital Management sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2017, closing a stake of 49,372 shares — an estimated $455K sold.

Highbridge Capital Management first reported a position in OMED in Q3 2016 and held it in 3 quarters. The position peaked at $493K in Q3 2016. 68 funds tracked by Wall St. Rank hold OMED as of Q2 2017.

  • Highbridge Capital Management reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 49,372 OncoMed Pharmaceuticals, Inc. shares in Q2 2017, an estimated $455K.
  • Highbridge Capital Management first reported a position in OncoMed Pharmaceuticals, Inc. in Q3 2016 and held it in 3 quarters.
  • Highbridge Capital Management's OncoMed Pharmaceuticals, Inc. position peaked at $493K in Q3 2016.
  • 68 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2017.

Based on Highbridge Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.